Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: Quidel And Labcorp Finish Big Year For IVD Deals With Major Acquisitions

Executive Summary

Quidel will pay $6bn for Ortho Clinical Diagnostics. Labcorp will acquire Personal Genome Diagnostics for $575m.

You may also be interested in...



JPM 2022 Mid-Week IVD Roundup: Guardant, Illumina, Ortho Clinical, Thermo Fisher

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022. Here are some highlights from the in vitro diagnostics companies that presented on the first two days of the meeting.

Personal Genome Diagnostics And Cleveland Diagnostics Will Use New Funding To Expand Cancer Portfolios

Personal Genome Diagnostics will use its funding to expand its liquid biopsy portfolio. Cleveland Diagnostics plans to develop early detection tests for lung and breast cancer.

News We’re Watching: Two Join Illumina Board, FDA Plans Health Equity Meeting, Pre-Eclampsia Test Cleared

This week, Illumina’s board added two independent members; the VA and the FDA agreed to collaborate on supply chain issues; and Think Surgical, Thermo Fisher Scientific and Blue Earth all landed FDA clearances.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel